INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.

Slides:



Advertisements
Similar presentations
Reference Anker SD. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448. The FAIR-HF Trial Ferric.
Advertisements

AbstractSchema Conclusion Pharmacokinetic profile of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous.
Iron and Vitamin B1 陳慧君 Iron  The most common deficiency of a single nutrient in both the developing and the developed world  Dietary iron.
Clinical Calculation 5th Edition
Selected Clinical Calculations
What is an IV push medication?
Assessment of Iron Status
Pharmacokinetics as a Tool
Calculating Heparin Bolus Dosage and IV Rate
Pharmacokinetics of Drug Absorption
Nonlinear pharmacokinetics
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Gokaraju Rangaraju College of Pharmacy
Week 6- Bioavailability and Bioequivalence
Quantitative Pharmacokinetics
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
1 I4E-MC-JXBA and JXBB Phase 2 Study to Evaluate the PK and Drug-Drug Interaction of Cetuximab and Cisplatin (JXBA) Cetuximab and Cisplatin (JXBB)
Martina Sahre1, Sreedharan Sabarinath1, PhD Maria Grant2, MD,
RESEARCH Lymphatic Targeting of Tenofovir; Intracellular Pharmacokinetics and Viral Dynamics Arnold Fridland, Ph.D, William Lee, Ph.D. Gilead Sciences,
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
Dr. Sadia Batool Shahid PGT-M-Phil, Pharmacology
Bioavailability Dr Mohammad Issa.
Objective: To utilize preclinical and phase I PK/PD data from a new quinolone (Q) and relevant public domain data to develop an exposure-response model.
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
One Compartment Open Model IV bolus
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Determination of Iron, Folic Acid and Vitamin B12.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
Drug Dosages and Intravenous Calculations
1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
Clinical Pharmacokinetic Equations and Calculations
A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.
The General Concepts of Pharmacokinetics and Pharmacodynamics
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
415 PHT Plasma Level – Time Curve
Total Iron Binding Capacity (TIBC)
KJ Hansen, JK Simons, TA Peterson 3M’s hMTS provides intradermal delivery of relatively high volumes of liquid API formulations. Infusion time may be anywhere.
The use of Ferinject® (ferric carboxymaltase) in the treatment of iron deficiency in patients with renal anaemia Dr D Farrugia Dr S Ramakrishna E Gibson.
Introduction Iron deficiency is commonly identified in endurance runners due to prolonged training and repeated ground impacts causing iron losses through.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MULTIPLE DOSAGE REGIMEN
Drug Response Relationships
Medical Directorate, National Kidney Foundation, Singapore
Serum albumin Albunex Optison™ IV infusion
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
Volume 9, Issue 8, Pages (August 2017)
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
Pharmacokinetics.
Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain.
Pharmacokinetics.
Technosphere® Inhaled Human Insulin has a More Rapid Onset of Action Than Subcutaneous Insulins - Meta Analysis of Clamp data From Three Clinical Studies.
Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second.
Use of Periodic Intravenous Iron Sucrose for Routine Iron Supplementation in Children with Inflammatory Bowel Disease Istvan Danko, MD, PhD Department.
Selected Bioavailability and Pharmacokinetic Calculations
Volume 54, Issue 2, Pages (August 1998)
Recent experience with high-dose intravenous iron administration
Yang Liu, Anne Chain, Rebecca Wrishko,
The FAIR-HF Trial Reference
Erythropoietin and iron
Volume 55, Issue 5, Pages (May 1999)
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Within-Subject Variability of Insulin Exposure and Metabolic Activity Following Replicate Doses of Technosphere® Insulin Inhalation Powder (TI) in Patients.
Presentation transcript:

INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division of Clinical Pharmacology V Office of Clinical Pharmacology Office of Translational Sciences CDER, FDA

OVERVIEW Chemistry and dosing regimen Iron transport and storage Pharmacokinetic profile Pharmacodynamic profile Conclusions

INJECTAFER

INJECTAFER (Ferric carboxymaltose) Single Dose Vials ( 2mL and 10 mL; 50 mg iron in each mL) Supplied as a dark brown, sterile, aqueous, isotonic solution Injected undiluted or infused following dilution in 250 mL saline

Dosing Regimen Proposed Dose: 15mg/kg; Maximum single weekly doses of 1,000 mg Total Dose: Maximum Total Dose of 2,500 mg given over 3 weeks Administered either by rapid intravenous (IV) push injection or by IV infusion. 600 to 1,000 mg doses: IV infusion over ≥ 15 minutes or undiluted IV push injection over 15 minutes < 500 mg doses: undiluted IV push injection at 100 mg per minute

Iron Transport and Storage Iron Transport and Storage PK Parameter: –Total Serum Iron Concentration PD Parameters: –Transferrin Saturation: TS is estimated by measures of total iron binding capacity (TIBC) and serum iron –Serum ferritin: an iron-storage protein

Dose Escalation PK/PD Study A single-center, randomized, double-blind, placebo-controlled multiple dose study Study included single IV doses of 100, 500, 800 and 1,000 mg via IV infusion or bolus (Injectafer; n = 6, placebo; n = 2) A total of 32 patients were studied

Total Serum Iron Concentrations Vs. Time

PK Parameters: Total Serum Iron Outcome 100 mg 500 mg 800 mg 1,000 mg Cmax (µg/mL) 37(4)157(19)324(64)333(42) AUC 0-72 (µg-h/mL) 432(75)2365(332)5252(1042)6415(1516) CL(mL/min)4.4(0.9)3.5 (0.5) (0.5)2.59(0.5)2.7(0.6) Average (SD) Normal serum iron concentration range is 4-15 µg/mL (LabCorp)

PD for Injectafer: Serum Ferritin Parameters Serum Ferritin 100 mg 500 mg 800 mg 1,000 mg Pre-dose(ng/mL)2(2)5(7)4(3)3(2) Max. Conc. (ng/mL) 49(20)423(400)488(165)652(218) Peak (Hours) Average (Standard Deviation) Normal Ferritin Concentrations: Male: ~ ng/mL Female: ~ ng/mL

PD for Injectafer: Transferrin Saturation

Summary: PK/PD Study Serum Iron Concentrations –increased with increasing Injectafer doses –increase in AUC was higher than expected for dose proportionality Serum Ferritin Concentrations –increased with increasing Injectafer doses –More than twice upper bound for normal serum ferritin with 1000 mg Injectafer dose Transferrin Saturation Increased/assay problems

CONCLUSIONS Clinical pharmacology data indicated increased levels of serum iron, serum ferritin and transferrin saturation in blood after Injectafer administration Data support the ability of Injectafer to replenish body iron stores Higher Injectafer doses produce ferritin levels that exceed normal human values